Net profit of Glaxosmithkline Pharmaceuticals rose 35.17% to Rs 262.87 crore in the quarter ended March 2025 as against Rs 194.48 crore during the previous quarter ended March 2024. Sales rose 4.79% to Rs 974.37 crore in the quarter ended March 2025 as against Rs 929.80 crore during the previous quarter ended March 2024.
For the full year,net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024.
| Particulars | Quarter Ended | Year Ended |
| Mar. 2025 | Mar. 2024 | % Var. | Mar. 2025 | Mar. 2024 | % Var. |
| Sales | 974.37 | 929.80 | 5 | 3749.21 | 3453.71 | 9 |
| OPM % | 34.20 | 27.67 | - | 31.40 | 26.31 | - |
| PBDT | 373.29 | 286.32 | 30 | 1321.98 | 1029.48 | 28 |
| PBT | 358.57 | 268.22 | 34 | 1255.19 | 959.80 | 31 |
| NP | 262.87 | 194.48 | 35 | 927.58 | 589.96 | 57 |